IntegriChain Appoints New Chief AI and Technology Officer to Lead Next Era of Innovation, Automation, and Customer Experience in Life Sciences
IntegriChain, a recognized market leader in net revenue optimization technology and commercial data insights for the life sciences industry, today announced a significant evolution in its leadership structure that underscores its commitment to advancing innovation, automation, and customer value delivery. The company revealed that Shai Fiss has been appointed as the new Chief AI and Technology Officer (CAIO & CTO), effective immediately. At the same time, Brad Burget, who has served as Chief Technology Officer for more than a decade, will transition into the newly established role of CTO Emeritus, focusing on a strategic channel transformation program.
This leadership evolution represents more than just a reshuffling of roles—it marks a deliberate step in IntegriChain’s long-term strategy to embed artificial intelligence (AI) and automation at the very core of its product and technology platform, further aligning the company with the rapidly shifting needs of pharmaceutical manufacturers and healthcare providers.
IntegriChain’s Market Position and the Context for Change
IntegriChain has built a strong reputation as a trusted partner for pharmaceutical, biotechnology, and emerging life sciences companies seeking to optimize net revenue, manage gross-to-net challenges, and unlock greater efficiency across their commercial operations. Its solutions sit at the intersection of data, technology, and strategy, helping life sciences enterprises manage the complexities of revenue management, payer negotiations, rebates, contracts, and compliance requirements.
The life sciences landscape is currently undergoing a profound transformation. The explosion of artificial intelligence and machine learning applications in healthcare, combined with increasing pricing scrutiny, shifting payer models, and evolving global regulations, has created both unprecedented opportunities and challenges. Companies in this sector are now seeking not just incremental improvements but radical automation capabilities that streamline operations, ensure compliance, and improve agility in decision-making.
For IntegriChain, the timing of this leadership change is deliberate. By appointing an executive deeply experienced in AI-driven product development, the company is doubling down on its mission to deliver scalable, intelligent, and human-centered digital platforms that improve customer experiences while enabling life sciences companies to thrive in this new era of complexity.
Shai Fiss: Bringing AI, SaaS, and Healthcare Expertise to the Helm
The newly appointed CAIO & CTO, Shai Fiss, brings with him an extensive background in building and scaling high-growth SaaS platforms and enterprise technologies. Over his career, he has been at the forefront of AI adoption within product development and healthcare workflows, which makes his expertise particularly relevant to IntegriChain’s future.
In his new role, Fiss will be responsible for overseeing the entire Product and Technology organization. His primary mandate will be to drive automation across customer-facing net revenue workflows and the company’s commercial data management solutions. His leadership is expected to accelerate the company’s ability to scale, innovate, and meet the demands of customers who increasingly expect AI-enabled tools that go beyond traditional software capabilities.
Speaking about his vision, Fiss emphasized his human-centered approach to digital transformation:
“I am passionate about transforming healthcare through intelligent, human-centered digital platforms. My mission is to advance and scale our core technologies to streamline operations, accelerate decision-making, and deliver next-generation digital experiences. I look forward to collaborating with the talented team at IntegriChain to expand our product capabilities and create greater value for our clients.”
This focus on both innovation and human-centered design reflects the broader philosophy that while AI and automation are central to the company’s next chapter, they must ultimately serve the people—whether customers, patients, or healthcare professionals—who rely on these technologies.
The CEO’s Perspective: A Pivotal Moment for AI in Life Sciences
Josh Halpern, CEO of IntegriChain, highlighted the strategic importance of this leadership change.
“We are at a pivotal moment, with customers asking for our answers to the innovation explosion in AI,” Halpern said. “Shai’s expertise will be instrumental in generating a new approach to embedding automation and guiding our next chapter of growth. His leadership will accelerate execution across the full product lifecycle while ensuring deep technical leadership remains at the core of our strategy.”
Halpern’s statement reflects a broader industry truth: pharmaceutical and biotech companies are no longer satisfied with basic data management tools. Instead, they expect predictive, proactive, and adaptive platforms that help them anticipate challenges, model complex revenue outcomes, and optimize operations in real-time.
By bringing in a technology leader with a proven track record in AI integration, IntegriChain is positioning itself to remain not just relevant but indispensable in the evolving healthcare technology ecosystem.
The Transition of Brad Burget to CTO Emeritus
While the appointment of Fiss represents a future-forward step, the contributions of Brad Burget, who has served as CTO for more than a decade, cannot be overstated. Burget has played a pivotal role in building IntegriChain’s current technology foundation, leading the company through multiple phases of rapid growth, platform expansion, and operational maturity.
As CTO Emeritus, Burget will focus on one of the company’s most critical strategic priorities: the channel transformation program. This initiative is designed to enhance the way IntegriChain’s solutions integrate with partner ecosystems, scale technical capabilities, and deepen value for customers across distribution and payer networks.
Halpern expressed deep gratitude for Burget’s service and foresight:
“Brad’s leadership contributions have been instrumental in our incredible progress and achievements, solidifying us as a market leader and innovator. We sincerely thank him for guiding our teams through rapid growth and for building a strong, highly skilled team of professionals who will continue to thrive under Shai’s leadership.”
Burget’s transition allows him to apply his extensive institutional knowledge to a more targeted strategic focus while ensuring continuity and technical excellence remain hallmarks of IntegriChain’s DNA.
Broader Industry Implications: AI, Automation, and the Future of Revenue Management
The timing of this leadership transition is not coincidental. Across the life sciences industry, there is a surge of interest in AI-driven automation, particularly in areas that have traditionally been manual, resource-intensive, and highly complex. Net revenue management is one such domain.
Pharmaceutical companies face mounting pressure from regulators, payers, and the public to ensure pricing transparency, optimize rebate structures, and comply with intricate reporting requirements. Manual workflows and siloed systems are no longer sufficient to keep pace. This has created an urgent demand for solutions that:
- Automate gross-to-net processes with precision and compliance.
- Integrate disparate datasets from payers, distributors, and healthcare providers.
- Predict market and payer behavior to support strategic pricing and contracting decisions.
- Enable scalability to manage new product launches, global expansion, and evolving regulatory landscapes.
IntegriChain’s pivot toward embedding AI directly into its platforms is an acknowledgment of this reality. By investing in leadership that prioritizes creative automation efficiencies, the company is not just keeping pace with competitors—it is actively shaping the future of how life sciences companies manage their most critical revenue processes.
The Human Element: Balancing Technology and Customer Experience
One of the unique aspects of IntegriChain’s announcement is its emphasis on not only technology innovation but also customer experience. The leadership changes are designed to ensure that as automation becomes more deeply embedded, customers feel supported, empowered, and guided through the transition.
The risk with any technological shift—particularly one as profound as AI integration—is that the human connection can be lost. IntegriChain’s messaging makes clear that its strategy is to balance technical excellence with empathy, usability, and customer partnership.
This dual focus is crucial in an industry like life sciences, where the stakes are high, workflows are complex, and compliance requirements are unforgiving. IntegriChain’s long-term success will likely hinge on its ability to combine the efficiency of machines with the insight and care of human expertise.
IntegriChain’s Next Chapter
As IntegriChain enters this new era, several themes are likely to define its trajectory:
- Scalable AI Integration — Leveraging Fiss’s expertise to embed automation across all core workflows.
- Product Expansion — Developing new capabilities that extend beyond traditional revenue management into adjacent areas of commercial operations.
- Channel Transformation — Led by Burget, ensuring seamless ecosystem integration and enhanced value delivery.
- Customer-Centered Innovation — Balancing cutting-edge AI with human-centered design to ensure usability and adoption.
- Industry Leadership — Positioning IntegriChain not just as a service provider, but as a thought leader in the convergence of AI, automation, and life sciences commercialization.
The appointment of Shai Fiss as Chief AI and Technology Officer and the transition of Brad Burget to CTO Emeritus represent a carefully planned evolution in IntegriChain’s leadership. More than just a personnel shift, it reflects the company’s broader strategy to embrace AI-driven innovation, scale its platforms, and deliver unmatched value to life sciences customers navigating an increasingly complex environment.
With a clear vision, deep technical expertise, and a commitment to balancing automation with customer experience, IntegriChain is well-positioned to shape the future of net revenue optimization and commercial data management in healthcare.
